

Understanding the Role for Novel PK Activation Strategies in Hemoglobinopathies: Developments in Sickle Cell Disease

Reference	Link
Brown JR, et al. FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease. <i>Blood</i> . 2020;136(Supp1):19-20.	https://ashpublications.org/blood/article/136/Supplement%201/19/470412/FT-4202-an-Allosteric-Activator-of-Pyruvate-Kinase
Carroll CP, et al. Acute pain treatment in patients with sickle cell disease transitioned to buprenorphine: evidence of equivalent pain relief. <i>Sickle Cell Dis</i> . 2025;2(1):yoaf014).	https://doi.org/10.1093/jscdis/yoaf014
Crizanlizumab-tmca (Adakveo [®]). PI 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761128s000lbl.pdf . URLs accessed 9.17.2025.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761128s000lbl.pdf
Crosby LE, et al. A biopsychosocial model for the management of patients with sickle-cell disease transitioning to adult medical care. <i>Adv Ther</i> . 2015;32(4):293-305.	https://pmc.ncbi.nlm.nih.gov/articles/PMC4415939/
Coyne PJ. Editorial for “Acute pain treatment in patients transitioned to buprenorphine: evidence of equivalent pain relief. <i>Sickle Cell Dis</i> . 2025;2(1):yoaf005.	https://doi.org/10.1093/jscdis/yoaf005
Exagamglogene autotemcel (Casgevy [®]) website. Available at: https://www.casgevy.com/ . URL accessed 9.17.2025.	https://www.casgevy.com/
Forma Therapeutics ASH Investors Briefing 12/13/2021. Available at: https://www.sec.gov/Archives/edgar/data/1538927/000119312521354602/d231942dex992.htm . Accessed 9/17/2025.	https://www.sec.gov/Archives/edgar/data/1538927/000119312521354602/d231942dex992.htm
Frangoul H, et al. <i>Exagamglogene Autotemcel for Severe Sickle Cell Disease</i> . <i>N Engl J Med</i> . 2024;390(18):1649-1662.	https://www.nejm.org/doi/10.1056/NEJMoa2309676?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed
Gummadi S, Kandula VN. A REVIEW ON ELECTROPHORESIS, CAPILLARY ELECTROPHORESIS AND HYPHENATIONS. <i>Int J Pharm Sci Res</i> . 2020;11(12):6038-6056.	https://ijpsr.com/bft-article/a-review-on-electrophoresis-capillary-electrophoresis-and-hyphenations/
HemePathReview website. Hemoglobin electrophoresis. Available at: https://hemepathreview.com/Heme-Review/HemoglobinElectrophoresis.pdf . Accessed 9.17.2025.	https://hemepathreview.com/Heme-Review/HemoglobinElectrophoresis.pdf
Idowu M, et al. Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial. <i>Lancet Haematol</i> . 2025;12(1):e35-e44.	https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00319-3/abstract

<p>Kanter J, et al. Etavopivat reduces incidence of vaso-occlusive crises in patients with sickle cell disease: HIBISCUS trial phase 2 results through 52 weeks. Global Sickle Cell Disease Network (GSCDN) 2025: Poster. Available at: https://sciencehub.novonordisk.com/congresses/GSCDN2025/julie-kanter.html. Accessed 9/17/2025.</p>	<p>https://sciencehub.novonordisk.com/congresses/GSCDN2025/julie-kanter.html</p>
<p>L-glutamine oral powder (Endari™). Prescribing information (PI) 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208587s000lbl.pdf. URLs accessed 9.17.2025.</p>	<p>https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208587s000lbl.pdf</p>
<p>Lovotibeglogene autotemcel (Lyfgenia®) website. Available at: https://www.lyfgenia.com/. URLs accessed 9.17.2025.</p>	<p>https://www.lyfgenia.com/</p>
<p>Odievre M-H, et al. <i>Indian J Med Res.</i> 2011;134:532-537. National Blood, Lung and Heart Institute (NBLHI). What is sickle cell disease? Available at: https://www.nhlbi.nih.gov/health-topics/sickle-cell-disease. Accessed 9/17/2025.</p>	<p>https://www.nhlbi.nih.gov/health-topics/sickle-cell-disease</p>
<p>Piel FB, et al. Global Burden of Sickle Cell Anaemia in Children under Five, 2010–2050: Modelling Based on Demographics, Excess Mortality, and Interventions. <i>PLoS Med.</i> 2013.10(7):e1001484.</p>	<p>https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001484</p>
<p>Salinas Cisneros G, Thein SL. Recent Advances in the Treatment of Sickle Cell Disease. <i>Front Physiol.</i> 2020;11:435.</p>	<p>https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2020.00435/full</p>
<p>Sayani F, et al. Thalassemia, sickle cell disease, and other hemoglobinopathies. In: Cuker A, et al (eds). American Society of Hematology Self-Assessment Program (ASH-SAP), 7th ed. ASH; 2019.</p>	<p>https://doi.org/10.1182/ashsap7.chapter07</p>
<p>Telen MJ. Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events? <i>Blood Adv.</i> 2020;4(14):3457-3465.</p>	<p>https://ashpublications.org/bloodadvances/article/4/14/3457/461584/Curative-vs-targeted-therapy-for-SCD-does-it-make</p>
<p>Thein SL, Howard J. How I treat the older adult with sickle cell disease. <i>Blood.</i> 2018;132(17):1750-1760.</p>	<p>https://ashpublications.org/blood/article/132/17/1750/39513/How-I-treat-the-older-adult-with-sickle-cell</p>
<p>Tisdale JF, et al. Treating sickle cell anemia. <i>Science.</i> 2020;367(6483):1198-1199.</p>	<p>https://pmc.ncbi.nlm.nih.gov/articles/PMC7299198/</p>
<p>Twumasi S, et al. A Comparative Analysis of Haemoglobinopathy Diagnostic Techniques—The Ghanaian Picture and the Way Forward: A Narrative Review. <i>Health Sci Rep.</i> 2025;8(9):e71223.</p>	<p>https://pmc.ncbi.nlm.nih.gov/articles/PMC12420352/</p>
<p>van Dijk MJ, et al. One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study. <i>Blood Adv.</i> 2023;7(24):7539-7550.</p>	<p>https://pmc.ncbi.nlm.nih.gov/articles/PMC10761354/</p>

<p>Voxelotor (Oxbryta™) PI 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf. URLs accessed 9.17.2025.</p>	<p>https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf.</p>
<p>Xu JZ, Vercellotti GM. Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease. <i>Hematology Am Soc Hematol Educ Program</i>. 2023;2023(1):107-113.</p>	<p>https://pmc.ncbi.nlm.nih.gov/articles/PMC10727103/</p>
<p>Xu JZ, et al. A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease. <i>Blood</i>. 2022;140(19):2053-2062.</p>	<p>https://www.sciencedirect.com/science/article/pii/S0006497122006632</p>

All URLs accessed October 20, 2025